HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept
{
"url": "https://lda.senate.gov/api/v1/filings/cf1b0c39-b925-42bd-b037-10c532ddbfe8/?format=api",
"filing_uuid": "cf1b0c39-b925-42bd-b037-10c532ddbfe8",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2017,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/cf1b0c39-b925-42bd-b037-10c532ddbfe8/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "140000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Paul Varki",
"dt_posted": "2017-04-19T17:20:30.473000-04:00",
"termination_date": null,
"registrant_country": "United States of America",
"registrant_ppb_country": null,
"registrant_address_1": "600 LEE ROAD SUITE 100",
"registrant_address_2": null,
"registrant_different_address": false,
"registrant_city": "WAYNE",
"registrant_state": "PA",
"registrant_zip": "19087",
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 43561,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": "19087",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "MADELINE SCHERWITZKY",
"contact_telephone": "+1 425-523-8565",
"dt_updated": "2022-04-06T16:06:32.276341-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Provisions related to abuse-deterrent opioid exclusivity",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids\nProvisions related to the reauthorization of the Prescription Drug User Fee Act\n1st Amendment/Communications with payors/off-label policy issues\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "Issues related to DEA quotas of Schedule I and II controlled substances\nS. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
}